NCT02374047View on ClinicalTrials.gov

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Hypercholesterolemia
Interventions
DRUG

CAT-2054

DRUG

Placebo

DRUG

CAT-2054-C

DRUG

Atorvastatin

Trial Locations (1)

53095

Spaulding Clinical Research, West Bend

Sponsors
All Listed Sponsors
lead

Catabasis Pharmaceuticals

INDUSTRY

NCT02374047 - A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects | Biotech Hunter | Biotech Hunter